Community Practice Connections : 11th Annual New York Lung Cancer Symposium
WebcastFaculty
OVERVIEW
Community Practice Connections : 11th Annual New York Lung Cancer Symposium is organized by Physicians Education Resource, LLC (PER) and would be held during Feb 28, 2017 - Feb 28, 2018.
The target audience for this medical event for oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate. This CME Conference has been approved with a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Objectives are :
• Assess methods by which prognostic and predictive tumor characteristics can be identified in advanced forms of lung cancer.
• Use tumor and patient characteristics to optimize personalized treatment sequencing for patients with advanced non–small cell lung cancer (NSCLC).
• Discuss current and emerging roles for single agent and combination immunotherapeutic strategies in the management of advanced lung cancers.
• Apply personalized approaches to manage EGFR-mutated advanced NSCLC by assessment of mutation subtypes in multiple lines of care.
• Assess evolving data sets concerning the use of ALK inhibition in front-line and subsequent lines of care in advanced NSCLC.
• Explain clinical trial evidence and their application concerning VEGF axis targeting in advanced NSCLC.
• Explain the role of chemotherapeutic strategies as a method to personalize care in patients with lung cancer.
• Integrate personalized approaches to manage challenging cases in advanced lung cancer settings.
Additional details will be posted as soon as they are available.
The target audience for this medical event for oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate. This CME Conference has been approved with a maximum of 2.0 AMA PRA Category 1 Credits.
Conference Objectives are :
• Assess methods by which prognostic and predictive tumor characteristics can be identified in advanced forms of lung cancer.
• Use tumor and patient characteristics to optimize personalized treatment sequencing for patients with advanced non–small cell lung cancer (NSCLC).
• Discuss current and emerging roles for single agent and combination immunotherapeutic strategies in the management of advanced lung cancers.
• Apply personalized approaches to manage EGFR-mutated advanced NSCLC by assessment of mutation subtypes in multiple lines of care.
• Assess evolving data sets concerning the use of ALK inhibition in front-line and subsequent lines of care in advanced NSCLC.
• Explain clinical trial evidence and their application concerning VEGF axis targeting in advanced NSCLC.
• Explain the role of chemotherapeutic strategies as a method to personalize care in patients with lung cancer.
• Integrate personalized approaches to manage challenging cases in advanced lung cancer settings.
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links